GSK 3532795

Drug Profile

GSK 3532795

Alternative Names: BMS 955176; GSK3532795; HIV maturation inhibitor

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer GlaxoSmithKline; ViiV Healthcare
  • Class Antivirals; Small molecules
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 01 Mar 2017 ViiV Healthcare withdraws a phase I trial in volunteers in USA prior to enrolment, due to neuropsychiatric serious adverse events reported by two participants (NCT02576119)
  • 31 May 2016 Bristol-Myers Squibb completes a pharmacokinetic phase I trial in HIV (In volunteers) in USA (NCT02715479)
  • 01 May 2016 Bristol-Myers Squibb terminates phase I trial in Healthy volunteers in USA (PO) (NCT02608918)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top